Author： Muññoz Miguel Bernabeu-Wittel Joséé Coveññas Rafael
Publisher： Informa Healthcare
ISSN： 1472-8222
Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.7, 2011-07, pp. : 889-897
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets, Vol. 12, Iss. 6, 2011-06 ,pp. :
Access to resources
Recommend
SCH 206272: a potent, orally active tachykinin NK 1 , NK 2 , and NK 3 receptor antagonist
By Anthes J.C. Chapman R.W. Richard C. Eckel S. Corboz M. Hey J.A. Fernandez X. Greenfeder S. McLeod R. Sehring S. Rizzo C. Crawley Y. Shih N.-Y. Piwinski J. Reichard G. Ting P. Carruthers N. Cuss F.M. Billah M. Kreutner W. Egan R.W.
European Journal of Pharmacology, Vol. 450, Iss. 2, 2002-08 ,pp. :
Signal Transduction in Human Cutaneous Melanoma and Target Drugs
Current Cancer Drug Targets, Vol. 13, Iss. 8, 2013-10 ,pp. :